People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Reunion Neuroscience, Inc. | — | Pharmaceuticals | Series D+ | $119.8M | $1.5B | 2024 |
| Cynapsus Therapeutics Inc. | — | Pharmaceuticals | Series B | $44.7M | $569.6M | 2011 |
| Trimel Pharmaceuticals Corp | — | Pharmaceuticals | Series A | $11.0M | $61.9M | 2014 |
Nathan Bryson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nathan Bryson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Briggs Morrison | 1 | 8 |
| Matthew Hawkins | 1 | 8 |
| Andrew Williams | 1 | 7 |
| Ansbert Gadicke | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| Michael Ehlers | 1 | 6 |
| David Hill | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Gregory Mayes | 1 | 5 |
| Edward Smith | 1 | 5 |
| Mark Theeuwes | 1 | 3 |
| Perry Molinoff | 1 | 3 |
| Ian Ihnatowycz | 1 | 3 |
| Julia Levy | 1 | 3 |
| Tamar D. Howson | 1 | 3 |
| Anthony Giovinazzo | 1 | 2 |
| Ellen Lubman | 1 | 2 |
| Tom Rossi | 1 | 2 |
| Ilan Oren | 1 | 2 |
| Rochelle Stenzler | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.